Literature DB >> 35274183

Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan.

Yoshiko Mori1,2, Kunihiko Amano3, Kenichi Chikatani3, Tetsuya Ito3, Okihide Suzuki3,4, Nao Kamae4, Satoshi Hatano3, Noriyasu Chika3, Azusa Yamamoto3, Keiichiro Ishibashi3, Hidetaka Eguchi5, Yasushi Okazaki5, Takeo Iwama3, Hideyuki Ishida3,4.   

Abstract

BACKGROUND: This study aimed to assess current trends in morbidity and mortality among patients with familial adenomatous polyposis (FAP). These data can be used for optimal surveillance and management of such patients.
METHODS: Data (November 2001 and April 2020) of genetically confirmed patients with FAP (n = 87) and their first-degree relatives with FAP phenotype (n = 20) were extracted from the Saitama Medical Center database. Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) were estimated using indirect method.
RESULTS: Overall, 46 men and 61 women were included; the median age at FAP diagnosis was 28.0 years for both. The SMR for all causes of death was 47.7 (95% confidence interval [CI] 19.1-98.2) in women and 26.5 (95% CI 9.73-57.8) in men. The SIR for colorectal cancer (CRC) was 860 (95% CI 518-1340) in women and 357 (95% CI 178-639) in men. The SMR for CRC was 455 (95% CI 93.7-1330) in women and 301 (95% CI 62.0-879) in men. Thirteen patients died during the observation period, and CRC was the leading cause of death (46%). Other causes of death included desmoid tumor (n = 2), small intestinal cancer (n = 2), ovarian cancer (n = 1), duodenal cancer (n = 1), and sepsis (n = 1).
CONCLUSIONS: The mortality ratio, estimated using SMR, remained high. CRC was the leading cause of death, whereas almost half of the causes of deaths were extra-colonic tumors. Life-long management of extra-colonic diseases may improve the prognosis in these patients.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  APC-associated polyposis; FAP-associated tumor; Familial adenomatous polyposis; Standardized incidence ratio; Standardized mortality ratio

Mesh:

Year:  2022        PMID: 35274183     DOI: 10.1007/s10147-022-02146-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  3 in total

1.  [Present status of familial polyposis of the colon in Japan-results of the nationwide survey (1961-1972)].

Authors:  J Utsunomiya; T Iwama; T Ichikawa; T Maki; T Miyanaga
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1973-07

2.  [A clinical genetic study on multiple intestinal polyposis and allied conditions].

Authors:  I Komatsu
Journal:  Jinrui Idengaku Zasshi       Date:  1968-03

3.  Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.

Authors:  Satoshi Tamada; Chihiro Kondoh; Nobuaki Matsubara; Ryuichi Mizuno; Go Kimura; Satoshi Anai; Yoshihiko Tomita; Masafumi Oyama; Naoya Masumori; Takahiro Kojima; Hiroaki Matsumoto; Mei Chen; Mengran Li; Kenji Matsuda; Yoshinobu Tanaka; Brian I Rini; Hirotsugu Uemura
Journal:  Int J Clin Oncol       Date:  2021-11-20       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.